REGULATION 33 OF SEBI LODR 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts more than Nifty Microcap 250 and 6.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unjha Formulations Ltd's Board of Directors approved unaudited financial results for the second quarter and half year ended 30 September 2025 on 10 November 2025. Net sales for Q2 FY26 stood at Rs 428.53 lakhs, up about 13% from Rs 378.19 lakhs in Q2 FY25, while total income from operations grew to Rs 434.74 lakhs. The company swung from a loss of Rs 11.06 lakhs in Q2 FY25 to a profit after tax of Rs 81.78 lakhs in Q2 FY26, with EPS rising from negative Rs 0.25 to Rs 1.83. For the half year, total income rose modestly to Rs 798.15 lakhs while PAT more than doubled to Rs 120.78 lakhs. The auditor (Jain & Golechha) issued a clean limited review report with no qualifications. Operating cash flow was healthy at Rs 103.99 lakhs for H1 FY26, and cash balances rose to Rs 160.08 lakhs.
Strong quarterly turnaround from loss to profit and over 100% PAT growth for the half year is positive for shareholders, though revenue growth remains modest and the base is small. The clean auditor report and improving cash position are supportive signals.